Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19001871 
Arai T, et al. (2008) Identification of beta-catenin as a novel substrate of Polo-like kinase 1. Cell Cycle 7, 3556-63 19001871
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Download Sites

S718-p - CTNNB1 (human)
Orthologous residues
CTNNB1 (human): S718‑p, CTNNB1 (mouse): S718‑p, CTNNB1 (rat): S718‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  bone cancer, cervical cancer, cervical adenocarcinoma, colorectal cancer, colorectal carcinoma
 Relevant cell lines - cell types - tissues:  293T (epithelial), HCT116 (intestinal), HeLa S3 (cervical), U2OS (bone cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PLK1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PLK1 (human) co-immunoprecipitation, siRNA inhibition of enzyme, phospho-motif antibody, transfection of constitutively active enzyme, transfection of inactive enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
doxycycline increase
nocodazole increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.